Around half of the patients with MM harbour BRAF mutations, of which 90% are BRAFV600 mutations that can be targeted with a combination of BRAF inhibitors/MEK inhibitors (MEK: mitogen-activated protein kinase inhibiting cell proliferation and inducing apoptosis) [33]. This evidence concerns the gene MAP2K7 and Miyoshi myopathy.